Satsuma Pharmaceuticals Inc

NASDAQ:STSA   4:00:00 PM EDT
0.89
+0.12 (+15.71%)
5:01:28 PM EDT: $0.89 0.00 (-0.39%)
Products, Regulatory

Satsuma Pharmaceuticals Announces Topline Results From Summit Phase 3 Trial Of STS101

Published: 11/14/2022 13:29 GMT
Satsuma Pharmaceuticals Inc (STSA) - Satsuma Pharmaceuticals Announces Topline Results From Summit Phase 3 Trial of Sts101 for the Acute Treatment of Migraine.
Satsuma Pharma - Sts101 Was Not Statistically Superior to Placebo at Two Hours Post-administration on Co-primary Endpoints in Study.
Satsuma Pharmaceuticals Inc - Sts101 Demonstrated a Favorable Safety and Tolerability Profile, Consistent With Clinical Trial Experience to Date.
Satsuma Pharmaceuticals -believes Results From Sts101 Phase 1 Pk & Ascend Phase 3 Long-term, Open-label Safety Trials to Support NDA Filing, Approval.
Satsuma Pharmaceuticals Inc - Does Not Plan to Invest in Commercializing Sts101 and Will Actively Explore Alternatives.